News

SynCo’s aseptic filling facility is able to fill and lyophilize a range of biopharmaceuticals which include monoclonal antibodies, nucleic acids, proteins, polysaccharides, aluminium containing vaccines, RNA and live

The contract allows Avaxia Biologics to complete the pre-clinical pharmacology studies for oral antibody therapy. Avaxia CEO Barbara Fox said they look forward to working with BARDA to

SurModics‘ net income was $3.84m, compared to net loss of $916,000 for the same period in the prior year. The company’s income from operations was $3.45m for the

Manufactured by Instituto Bioclon, Anascorp, Centruroides (Scorpion) Immune F(ab’)2 (Equine) Injection, is made from the plasma of horses immunized with scorpion venom. The FDA approval is based on

According to the agreement, Pluristem is expected to license worldwide rights to United Therapeutics to develop and commercialize the future product for the treatment of PH, however Pluristem

Earlier in October 2006, Biotica has licensed all rights of rapamycin analogue program to Wyeth Pharmaceuticals, which was acquired by Pfizer in October 2009. Biotica CEO Edward Hodgkin

Both the companies are expected to establish a Product Advisory Committee to manage the activities that are required to develop and seek approval for PCV and to pursue

The application works in conjunction with HP’s global printing partners who are able to print labels in high volumes even when required in some of the world’s most

BioClinica‘s net income was $924,000, compared to $403,000 for the same period in the prior year. The company’s income from operations were $1.48m for the second quarter ended